Phase 3 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), a condition where blood clots cause high blood pressure in the lungs
- People who are not suitable for surgery to remove the blood clots (called pulmonary thromboendarterectomy or PTE)
- People whose blood vessel anatomy and disease are suitable for a non-surgical procedure called balloon pulmonary angioplasty (BPA), which opens up blocked blood vessels in the lungs
- People who have not yet started any specific medical treatment for CTEPH or related pulmonary hypertension, but who are planning to begin both medication and BPA treatment
- People who are willing and able to give their agreement to participate and to attend scheduled visits and follow study requirements
Who may not be able to join:
- People with moderate to severe heart problems, specifically a weakened heart pump or significantly enlarged heart muscle
- People who have sarcoidosis (an inflammatory condition affecting multiple organs)
- People with active cancer
- People who have sickle cell anaemia
- People with severe liver disease
- People who are currently imprisoned
- People who are pregnant, planning to become pregnant, or currently breastfeeding
- People who are unable to have an MRI scan, for example due to metal fragments in the eye, severe claustrophobia, or inability to lie flat
- People for whom the medications riociguat or macitentan are not medically appropriate
- People whose physical or mental health conditions, in the treating doctor's judgement, could put them at unnecessary risk or make it difficult to follow the study requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sudarshan Rajagopal, MD, PhD, Duke Health System
Phone: +1 919 660 2026
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in end-systolic elastance (Ees) divided by arterial elastance (Ea) (Ees/Ea) at three time points: Baseline, Timepoint 1 and Timepoint 2.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.